Essity Q1 margins rise on volume growth and acquisition gains

This print is more important for margin durability than for headline growth. In a category where pricing power is usually the first casualty of weak consumer demand, the combination of mix resilience, lower input costs, and working-capital release suggests Essity is entering the year with operating leverage that can persist even if reported top-line remains noisy from FX. The market should focus on the gap between reported EPS and cash generation: that spread can fund buybacks and deleveraging simultaneously, which typically supports valuation multiples even without strong nominal revenue growth.

The new feminine care asset looks strategically better than the headline purchase price implies because it deepens a North America franchise where scale matters for retailer shelf positioning, promo efficiency, and procurement. The second-order effect is pressure on smaller branded competitors and private label in feminine care, as a better-capitalized incumbent can defend shelf space with fewer margin concessions than before. That said, the transaction also raises integration and post-close synergy execution risk over the next 2-3 quarters; any slip in volumes or margin accretion would show up first in Personal Care before it is visible at the group level.

The weak spot is Consumer Tissue, where Europe remains structurally exposed to price deflation and fragile consumer trade-down. If pulp, energy, and freight remain benign, management can mask this with mix and buybacks; if any of those inputs re-accelerate, the margin expansion story becomes much less linear. FX is the other key swing factor: with reported sales already materially distorted, the stock can still outperform operationally while the reported P&L stays capped for several months, which often creates a window for patient buyers before consensus fully resets.